An increased prevalence and incidence of cardiovascular disease is the most important clinical consequence of abdominal obesity. Although defects in glucose handling in skeletal muscle have been extensively investigated, they have failed to clarify why insulin resistance is linked to vascular disease. Non-classic actions of insulin such as those on haemodynamics, nerve function and haemostasis and on lipoprotein metabolism would appear of greater interest in this respect. It is now clear that obese individuals exhibit resistance to some of the non-classic effects of insulin. These include resistance to insulin action on large vessel compliance, nitric oxide-dependent stimulation of vasodilation in resistance vessels, activation of the sympathetic nervous system by insulin but not other stimuli, platelet antiaggregation and suppression of hepatic very low density lipoprotein production. The exact cause(s) of resistance to these non-classic insulin actions are unclear but their understanding would seem important to understand the links between obesity and cardiovascular disease.
Introduction
Insulin resistance in obesity has multiple potential causes and affects the function of several tissues ( Figure 1 ). The causes, which are likely to involve both environmental 1 and genetic 2,3 components, could be divided into those resulting from overeating and those resulting from abnormal activation of the hypothalamic ± pituitary ± adrenal axis (see Bjorntorp   1 for review). Since the studies performed over 35 y ago by Rabinowitz et al, 4 it has been clear that one target of insulin resistance in obesity is skeletal muscle. This aspect of insulin resistance, con®rmed by others over the years, 5 ± 7 has however mechanistically failed to explain the increased prevalence of cardiovascular disease in obesity. During recent years, several novel, non-classic actions of insulin have been described and found to be defective in obese individuals. The ensuing discussion will focus on defects in vascular actions of insulin.
Insulin action on resistance vessels
Pharmacology rather than physiology? Insulin is a true but a remarkably slow vasodilatator in skeletal muscle. 8 This effect appears to be nitrogen oxide (NO)-dependent, as it can be abolished by blocking NO-synthesis. 9, 10 However, even a doubling of basal blood¯ow by a high dose of insulin takes several hours, while maximal doses of typical endotheliumdependent vasodilatators, such as acetylcholine, double blood¯ow within a minute. 11 ± 13 The exact reason for the slow effect of insulin on blood¯ow is unknown. One possibility is that insulin, via rapid activation of the sympathetic nervous system, counteracts the vasodilatory effects of insulin.
14 Another possibility is that hyperpolarization, which follows insulin stimulation of Na , K ATPase, 15, 16 decreases intracellular Ca concentrations in vascular smooth muscle cells leading to vasorelaxation. 17 NO-dependence would in turn depend on hyperpolarization in the endothelial cells, which increases intracellular Ca concentrations and stimulates endothelial NO production. 18, 19 Insulin increases glucose uptake 10-fold within 30 min in skeletal muscle but does not change blood ow within this time frame. 11 This implies that defects in blood¯ow cannot modify insulin action on glucose uptake under physiological conditions.
Resistance vessel function in obesity and its relationship to endothelial function and sympathetic nervous system activation. The ability of high concentrations or prolonged infusions of insulin to increase peripheral blood¯ow is blunted in obese subjects. 6, 7 This defect does not, however, appear to contribute to impaired insulin stimulated glucose uptake as it is not observed under physiological conditions, 4 and as glucose uptake cannot be increased by endotheliumdependent vasodilatory agents such as bradykinin, which itself has no effect on glucose extraction. 20 Several factors could contribute to the defect in the insulin induced decrease in peripheral vascular resistance (terminal arterioles and proximal arteriolar segments) in obesity. First, an increase in basal activity of the sympathetic nervous system characterizes obese subjects, and could counteract insulin induced vasodilatation.
14 On the other hand, obesity is a condition characterized by impaired endothelium-dependent vasodilatation. 7, 20 Given that insulin-induced vasodilatation involves NO-production, endothelial dysfunction might also impede blood¯ow responses to insulin in obese subjects.
Insulin action on arterial stiffness
Arterial stiffness and insulin. Although resistance arteries are the major determinants of vascular resistance, aortic pressure can be regulated independent of peripheral blood pressure by altering compliance or vasodilatation of large arteries. 21 An increase in arterial compliance, in the face of unchanged peripheral vascular resistance, will decrease aortic systolic pressure and thereby left ventricular afterload, and enhance coronary perfusion during diastole. 21 The Atherosclerosis Risk in Communities (ARIC) Study was the ®rst to implement measurement of stiffness of the carotid artery, using a non-invasive ultrasound method, in a large population survey. This crosssectional study found that hyperinsulinaemia and hyperglycaemia contributed synergistically to arterial stiffness, independent of wall thickness, in both men and women. 22 We have recently employed pulse wave analysis 21 to determine acute effects of insulin on arterial stiffness in normal 23 and obese 24 subjects. We found insulin to diminish wave re¯ection at the level of the aorta (Figure 2 ). This change indicates, in the face of constant peripheral vascular resistance, increased compliance in vessels greater than the resistance arteries. 21, 23 The decrease in stiffness can be quantitated by an augmentation index, which is de®ned as the ratio of augmentation (pressure difference between the re¯ected and ®rst systolic wave in mmHg) divided by pulse pressure (mmHg). 21 Physiology rather than pharmacology? In another recent study, simultaneous recording of peripheral blood¯ow and the augmentation index under normoglycemic hyperinsulinemic (insulin $ 60 mUal) conditions revealed marked temporal dissociation in insulin action on peripheral blood¯ow and arterial stiffness. 25 The decrease in arterial stiffness by insulin became signi®cant in normal subjects within 30 min, while peripheral blood¯ow remained unchanged for the ®rst 120 min. The changes in augmentation and peripheral blood¯ow, were, however, signi®cantly interrelated, suggesting that insulin action on resistance and large vessels are altered in a similar direction in a given person. 25 Arterial stiffness in obesity. By employing the technique of pulse wave analysis, which allows measurement of compliance of the entire arterial tree independent of changes in peripheral vascular resistance, we have recently compared insulin's effect on arterial stiffness in obese and non-obese subjects. 24 These studies have identi®ed a clear defect in the normal action of insulin to diminish arterial stiffness. The mechanism underlying this defect is unknown but Vascular actions of insulin H Yki-Ja Èrvinen and J Westerbacka could, based on known NO-dependence of wave re¯ection, 26, 27 be yet another re¯ection of endothelial dysfunction in obesity. Whether the latter is a consequence of an insulin signalling defect in blood vessels, 28 or an indirect consequence of insulin resistance such as that resulting from elevated free fatty acid concentrations, is unknown. 29 Taken together the above data suggest that insulin's vascular effects follow a hierarchy where an increase in large vessel compliance precedes vasodilatation in the periphery. The latter effect is too slow to be of physiological signi®cance for regulation of vascular function, and its modulation by vasoactive agents does not ameliorate insulin resistance of glucose uptake in obesity. On the other hand, insulin diminishes arterial stiffness under physiological conditions. This novel action of insulin appears severely blunted in obesity and provides a potential mechanism linking obesity and cardiovascular disease. Figure 2 An example of the effect of euglycemic hyperinsulinemia (Insulin, 120 min insulin infusion at a rate of 1 mUakg Á min) as compared to infusion of saline (Control) on radial and aortic pulse waveforms in normal subjects. In the top panel, insulin can be seen, within 30 min of hyperinsulinemia, to decrease the amplitude of the re¯ected wave, ie augmentation (the pressure difference between the second and the ®rst systolic wave) in the absence of any change in pulse pressure (PP). The waveforms remain unchanged during the control study (bottom panel).
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